^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ABBV-514

    i
    Associations
    News

    Trials

    Company:
    AbbVie
    Drug class:
    CCR8 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Budigalimab (NCT05005403)
    Phase 1
    AbbVie
    Recruiting
    Last update posted :
    06/10/2024
    Initiation :
    11/01/2021
    Primary completion :
    05/04/2026
    Completion :
    05/04/2026
    PD-L1
    |
    Keytruda (pembrolizumab) • budigalimab (ABBV-181) • ABBV-514